BIIB093
Asset
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Not known
- 6
- Indications
- 54
- Trials
- 1
- Developer
Indications
6Acute stroke
Phase 3, Terminated, NCT02864953, clinicaltrials.gov, Oct 30, 2026
Brain edema
Phase 3, Terminated, NCT02864953, clinicaltrials.gov, Oct 30, 2026
Brain contusion
Phase 2, Terminated, NCT03954041, clinicaltrials.gov, Oct 30, 2026
3 more
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials54
- Evidence for its targets1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.